## Program

**11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy**

**March 24 – 27, 2010**

### Wednesday, March 24, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00–18:00</td>
<td><strong>Registration</strong> at the International Conference Centre (CICG)</td>
</tr>
<tr>
<td>16:30–17:00</td>
<td><strong>Welcome address:</strong></td>
</tr>
<tr>
<td></td>
<td>Ezio Giacobini and Gabriel Gold, Organizers</td>
</tr>
<tr>
<td></td>
<td>René Rizzoli, Head of the Department of Rehabilitation and Geriatrics,</td>
</tr>
<tr>
<td></td>
<td>Geneva University Hospitals</td>
</tr>
<tr>
<td></td>
<td>Bernard Gruson, General Director, Geneva University Hospitals</td>
</tr>
<tr>
<td></td>
<td>Jean-Louis Carpentier, Dean, Faculty of Medicine, University of Geneva</td>
</tr>
<tr>
<td></td>
<td>J. Kevin Dorsey, Dean, Southern Illinois University School of Medicine,</td>
</tr>
<tr>
<td></td>
<td>Springfield Minister of Health of the Republic and Swiss Canton of Geneva</td>
</tr>
<tr>
<td>17:00–18:00</td>
<td><strong>Opening Lecture:</strong></td>
</tr>
<tr>
<td></td>
<td>Richard Frackowiak (Lausanne, Switzerland)</td>
</tr>
<tr>
<td></td>
<td>London Taxi Drivers, Hippocampus and Alzheimer Disease</td>
</tr>
</tbody>
</table>

### Thursday, March 25, 2010

**Room A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15–08:35</td>
<td><strong>State of the art lecture:</strong> Serge Gauthier (Montreal, Canada)</td>
</tr>
<tr>
<td></td>
<td>Why so few drugs for AD? The question</td>
</tr>
</tbody>
</table>

**Why so Few Drugs for AD?**

*Chairs: Serge Gauthier and Lon Schneider*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:35–08:55</td>
<td>Robert Becker (South Freeport, USA) Why so few AD drugs? Could methods be failing drugs?</td>
</tr>
<tr>
<td>08:55–09:15</td>
<td>Cristina Sampaio (Lisbon, Portugal) Regulatory view point</td>
</tr>
<tr>
<td>09:15–09:35</td>
<td>Lon Schneider (Los Angeles, USA) The clinical trial: wrong target or wrong design?</td>
</tr>
<tr>
<td>09:35–09:55</td>
<td>Eric Siemers (Indianapolis, USA) Why so few drugs for AD? The drug company viewpoint</td>
</tr>
</tbody>
</table>

**09:55 – 10:25 Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:25–10:45</td>
<td><strong>State of the art lecture:</strong> Roger Nitsch (Zurich, Switzerland) Immunization: the future of AD therapy</td>
</tr>
</tbody>
</table>

**The Culprits: Monomers, Dimers, Trimers and Other Oligomers**

*Chairs: Roger Nitsch and Karen Ashe*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45–11:05</td>
<td>Karen Ashe (Minneapolis, USA) Fluctuating patterns of A-beta oligomers in AD</td>
</tr>
<tr>
<td>11:05–11:25</td>
<td>Stephen Strittmatter (New Haven, USA) Role of cellular prion protein in AD</td>
</tr>
<tr>
<td>11:25–11:45</td>
<td>Nibaldo Inestrosa (Santiago, Chile) Amyloid beta oligomers at brain synapses</td>
</tr>
<tr>
<td>11:45–12:05</td>
<td>William Klein (Chicago, USA) Synaptoxic A-beta oligomers (ADDLs): A molecular basis for the cause, diagnosis, and treatment of Alzheimer disease</td>
</tr>
</tbody>
</table>

**12:05 – 13:30 Lunch**

**From Bench to Bedside: Rationale for Early Diagnosis and Treatment in Alzheimer’s Disease**
Chair: Dale Schenk
13:30 – 13:35 | Introduction
13:35 – 14:00 | Christian Haass (Munich, Germany)
In vivo analysis of amyloid A-beta peptide inhibition and tau mediated neurotoxicity
14:00 – 14:25 | David Teplow (Los Angeles, USA)
A-beta oligomers: Therapeutic targets in AD
14:25 – 14:50 | Jean-François Dartigues (Bordeaux, France)
Identifying AD early: Is it possible?
14:50 – 15:10 | Questions and answers
(mini-symposium supported by Elan)

15:10 – 15:40 Break

Active and Passive Immunization
Chairs: Bengt Winblad and Dale Schenk
15:40 – 16:00 | Dale Schenk (South San Francisco, USA)
A-beta immunotherapy: Lessons learned on the role of A-beta in AD
16:00 – 16:20 | Ronald DeMattos (Indianapolis, USA)
A-beta immunotherapy: tailoring specific biomarkers for clinical development
16:20 – 16:40 | Bengt Winblad (Stockholm, Sweden)
Immunotherapy in AD: An update of present experience
16:40 – 17:00 | Ronald Black (Collegeville, USA)
A-beta immunotherapy in AD: Clinical evidence for disease modification

17:20 – 19:00 Reception with poster viewing and discussion

Thursday, March 25, 2010
Room B
08:15 – 08:35 | State of the art lecture: Jaakov Stern (New York, USA)
The impact of reserve on AD pathology

Imaging of the Brain: Testing Drug Effects
Chairs: Agneta Nordberg and Hilkka Soininen
08:35 – 08:55 | William Klunk (Pittsburgh, USA)
Amyloid imaging: strengths and weaknesses in drug development
08:55 – 09:15 | Hilkka Soininen (Kuopio, Finland)
MRI imaging of the brain: testing drug effects
09:15 – 09:35 | William Jagust (Berkeley, USA)
Imaging in drug development: It's not just amyloid
09:35 – 09:55 | Agneta Nordberg (Stockholm, Sweden)
Amyloid imaging in the evaluation of new drug therapy in AD

09:55 – 10:25 Break

10:25 – 10:45 | State of the art lecture: Renaud Du Pasquier (Lausanne, Switzerland)
Neurocognitive disorders associated with the human immunodeficiency virus

Emerging Novel Therapeutic Targets I
Chairs: Abraham Fisher and Pierre Dayer
10:45 – 11:05 | Abraham Fisher (Ness Ziona, Israel)
M1 muscarinic agonists: A powerful weapon in the anti-AD arsenal
11:05 – 11:25 | Achim Schneeberger (Vienna, Austria)
Alzheimer AFFITOPE vaccines
11:25 – 11:45 | Israel Hanin (Tucson, USA)
A-beta anti-aggregants
11:45 – 12:05 | Gerhard Koenig (Watertown, USA)
Nicotinic compounds for cognitive deficits
(session partially supported by Affiris GmbH, Austria; EnVivo Pharmaceuticals, USA)

12:05 – 13:30 Lunch
13:30 – 13:50  
*State of the art lecture: François Herrmann* (Geneva, Switzerland)  
Do intelligent and educated people live longer?

### Focusing on Early Diagnosis and Treatment of Alzheimer Disease

**Chairs: Steven DeKosky and John Morris**

13:50 – 14:10  
**Steven DeKosky** (Charlottesville, USA)  
Amyloid burden in normal and MCI patients

14:10 – 14:30  
**Jean-Marc Orgogozo** (Bordeaux, France)  
Identification of preementia AD with neuropsychological tests

14:30 – 14:50  
**Christoph Hock** (Zurich, Switzerland)  
Immunological features of healthy aging, MCI and Alzheimer disease

14:50 – 15:10  
**John Morris** (St. Louis, USA)  
Non-demented aging and preclinical Alzheimer disease

15:10 – 15:40  
**Break**

15:40 – 16:00  
*State of the art lecture: Dina Zekry* (Geneva, Switzerland)  
Oxidative stress in MCI and Alzheimer disease

### Prevention of AD

**Chairs: Laura Fratiglioni and Bruno Vellas**

16:00 – 16:20  
**Laura Fratiglioni** (Stockholm, Sweden)  
Alzheimer disease: Risk factors and prevention

16:20 – 16:40  
**Mia Kivipelto** (Stockholm, Sweden)  
Prevention of AD: is it possible? Nordic multi-domain intervention studies

16:40 – 17:00  
**Bruno Vellas** (Toulouse, France)  
The GuidAge study: New results

17:00 – 17:20  
**Patrizia Mecocci** (Perugia, Italy)  
Mitochondria: Targets of preventive therapy

17:20 – 19:00  
Reception with poster viewing and discussion

**Friday, March 26, 2010**

### Room A

### Advances in Neuroimaging for Alzheimer Disease

**Chairs: Mike Weiner and Samuel Svensson**

08:15 – 08:20  
Introduction

08:20 – 08:40  
**Michael Weiner** (San Francisco, USA)  
Biomarkers for monitoring the progression of AD in clinical trials: The Alzheimer disease neuroimaging initiative

08:40 – 09:00  
**Nick Fox** (London, UK)  
4D MRI: measuring change for early detection and monitoring of progression

09:00 – 09:20  
**Simon Lovestone** (London, UK)  
Combinatorial biomarkers of Alzheimer disease and the value of multimodal analysis

09:20 – 09:40  
**Eric Reiman** (Phoenix, USA)  
(18F)AZD4694 in the symptomatic and pre-symptomatic study of AD

09:40 – 09:55  
Discussion

(mini-symposium supported by AstraZeneca)

09:55 – 10:25  
**Break**

10:25 – 12:05  
**Developing the Next Generation of Treatment**  
(mini-symposium supported by Pfizer)

12:05 – 13:30  
**Lunch**

### Treatment of Alzheimer’s Disease – Short Term Benefits and Beyond

**Chair: Roy Jones**

13:30 – 13:40  
**Roy Jones** (Bath, UK)  
Introduction

13:40 – 14:10  
**Judith Saxton** (Pittsburg, USA)
Important aspects of communication in Alzheimer’s disease
14:10 – 14:40  
David Wilkinson (Southampton, UK)
Short and long-term treatment with memantine in Alzheimer’s disease
14:40 – 15:10  
Roy Jones (Bath, UK)
Memantine in Alzheimer’s disease: Outcomes in real-life
(mini-symposium supported by Lundbeck, A/S)

15:10 – 15:40  
Break

Emerging Hypotheses in Cholinesterase Inhibition: Targeted Activity for Optimal Effects
Chair: Lutz Frölich
15:40 – 15:45  
Chairman’s introduction
15:45 – 16:10  
Lutz Frölich (Mannheim, Germany)
Ambitious dementia treatment with high doses of cholinesterase inhibitors
16:10 – 16:35  
Roger Bullock (Swindon, UK)
Long-term effects of cholinesterase inhibition – the good, the bad, and the ugly!
16:35 – 17:00  
Sultan Darvesh (Halifax, Canada)
Possible mechanisms underlying effects of BuChE – emerging hypotheses to spark future research
17:00 – 17:15  
Questions from the audience
17:15 – 17:20  
Chairman’s conclusions
(mini-symposium supported by Novartis)

Friday, March 26, 2010
Room B

08:15 – 08:35  
State of the art lecture: Giancarlo Pepeu (Florence, Italy)
The brain cholinergic system is still alive

The Cholinergic System Still Exists
Chairs: Claudio Cuello and Filippo Drago
08:35 – 08:55  
Elliott Mufson (Chicago, USA)
The cholinergic system in AD: Shifts from survival to death
08:55 – 09:15  
Claudio Cuello (Montreal, Canada)
The cholinergic system is the most vulnerable to Alzheimer pathology
09:15 – 09:35  
Antonio Cattaneo (Pisa, Italy)
How to rescue the cholinergic system with NGF
09:35 – 09:55  
Maria Eriksdotter Jönhagen (Stockholm, Sweden)
Therapy of AD with NGF
09:55 – 10:25  
Break

10:25 – 10:45  
State of the art lecture: Kaj Blennow (Mölndal, Sweden)
Predictive biomarkers of early AD

Preclinical Models of AD and Neural Stem Cells
Chairs: Manfred Windisch and Karl-Heinz Krause
10:45 – 11:05  
Manfred Windisch (Graz, Austria)
Animal models of Alzheimer disease – their predictive value for drug development
11:05 – 11:25  
Kiminobu Sugaya (Orlando, USA)
Stem cells for AD treatment – Involvement of cytokine in APP induced glial differentiation of stem cells
11:25 – 11:45  
Greg Brewer (Springfield, USA)
Reversing epigenetic aging in cell models of AD
11:45 – 12:05  
Amelia Marutle (Stockholm, Sweden)
Stimulating regenerative mechanisms in Alzheimer disease
(session partially supported by JSW-Lifesciences GmbH, Austria)

12:05 – 13:30  
Lunch

13:30 – 13:50  
State of the art lecture: Rudolf Tanzi (Charlestown, USA)
Novel Alzheimer disease genes and emerging biological pathways
Cerebrovascular Pathology: Cognitive Consequences and Preventive Strategies
Chairs: Theodor Landis and Gabriel Gold

13:50 – 14:10  Gabriel Gold (Geneva, Switzerland)
  Mixed dementia: What have we learned from neuropathology?

14:10 – 14:30  Philip Scheltens (Amsterdam, The Netherlands)
  Subcortical ischemic vascular disease: What have we learned from MRI studies?

14:30 – 14:50  Amos Korczyn (Ramat Aviv, Israel)
  The vascular contribution to dementia

14:50 – 15:10  Ingmar Skoog (Göteborg, Sweden)
  Subcortical ischemic vascular disease: A target for prevention and treatment in dementia disorders

15:10 – 15:40 Break

15:40 – 16:00  State of the art lecture: Rodger Elble (Springfield, USA)
  Cerebrospinal fluid drainage in the treatment of dementia

Emerging Novel Therapeutic Targets II
Chairs: Beka Solomon and Harald Hampel

16:00 – 16:20  Suzanne Craft (Seattle, USA)
  Intranasal insulin improves cognition and modulates beta-amyloid in early AD

16:20 – 16:40  Harald Hampel (Frankfurt, Germany)
  Lithium trial in AD: A randomized, single-blinded, placebo-controlled multicentre 10-week study

16:40 – 17:00  Andy Protter (San Francisco, USA)
  Dimebon (Latrepirdine) – A therapeutic candidate for neurodegenerative diseases with a novel mechanism of action

17:00 – 17:20  Beka Solomon (Ramat Aviv, Israel)
  A new target for AD immunotherapy: Beta secretase
  (Session partially supported by Medivation, USA)

Saturday, March 27, 2010

Room A
08:15 – 08:35  State of the art lecture: Constantin Bouras (Geneva, Switzerland)
  The brain of the centenarians

Moving to TAU: An Obligatory Step Towards a Disease-Modifying Treatment in AD
Chairs: Khalid Iqbal and Panteleimon Giannakopoulos

08:35 – 08:55  Panteleimon Giannakopoulos (Geneva, Switzerland)
  The contribution of tau-related pathology in AD: What we really know?

08:55 – 09:15  Khalid Iqbal (Staten Island, USA)
  From tangles to tau protein: Biomarker and therapeutic opportunities

09:15 – 09:35  Eckhard Mandelkow (Hamburg, Germany)
  Tau and AD: From structure to transgenic mice and aggregation inhibitors

09:35 – 09:55  Karen Duff (New York, USA)
  Pathogenic mechanisms and therapeutic approaches for the tauopathies

09:55 – 10:25 Break

10:25 – 10:45  State of the art lecture: John Breitner (Seattle, USA)
  Bi-directional effect of naproxen on the pathogenesis of AD: Clinical and biological evidence
  from a randomized primary prevention trial

Non Alzheimer Disease Dementias: Diagnostic Issues and Treatment
Chairs: Philippe Robert and Roberto Bernabei

10:45 – 11:05  Bruno Dubois, (Paris, France)
  MCI: From the syndrome to the underlying disease

11:05 – 11:25  Ian McKeith (Newcastle, UK)
  Improving diagnosis in dementia with Lewy bodies (DLB)
11:25 – 11:45 Philippe Robert (Nice, France)
Treating early behavioral and psychological symptoms of dementias

11:45 – 12:05 Roberto Bernabei (Rome, Italy)
Dementia and multimorbidity: The importance of comprehensive geriatric assessment and treatment

12:05 – 13:30 Lunch

13:30 – 13:50 State of the art lecture: René Rizzoli (Geneva, Switzerland)
Vitamin D and cognitive function

Oral Communications III
Chairs: Andreas Monsch and Armin von Gunten LS
13:50 – 14:05 TBA
14:05 – 14:20 TBA
14:20 – 14:35 TBA
14:35 – 14:50 TBA
14:50 – 15:05 TBA
15:05 – 15:10 Discussion

15:10 – 15:40 Closing remarks

19:00 – 22:30 Speakers dinner (by invitation)

Saturday, March 27, 2010

Room B

08:15 – 08:35 State of the art lecture: Ezio Giacobini (Geneva, Switzerland)
Why so few drugs for AD? The answer

Emerging Novel Therapeutic Targets III
Chairs: Michael Murphy
08:35 – 08:55 Michael Murphy (Beverly Hills, USA)
Coming full circle – Refined patient phenotypes in disease modification therapy
08:55 – 09:15 Mene Pangalos (Collegeville, USA)
Disease modifying approaches for the treatment of AD
09:15 – 09:35 Pedro Pesini (Zaragoza, Spain)
The use of A-beta C-terminal peptides in the early diagnosis and preventive treatment of AD
09:35 – 09:55 Michal Novak (Bratislava, Slovak Republic)
Can we develop an anti-tau immunization therapy?
(session partially supported by Araclon Biotech, Spain; Worldwide Clinical Trials, USA and Wyeth Pharmaceuticals, USA)

09:55 – 10:25 Break

Oral Communications I
Chairs: Reto Kressig and Frédéric Assal
10:25 – 10:40 Vic Ramkumar (Springfield, USA)
Protective role of adenosine A1 receptor against beta-amyloid neurotoxicity
10:40 – 10:55 Taher Darreh-Shori (Stockholm, Sweden)
Apolipoprotein E and A-beta may affect cholinergic neurotransmission
10:55 – 11:10 Ildiko Szanto (Geneva, Switzerland)
Aging related pathologies and oxidative stress
11:10 – 11:25  Amy Arai (Springfield, USA)
Modification of synaptic transmission and plasticity in AD-transgenic mice
11:25 – 11:40  Nigel Greig (Baltimore, USA)
GLP-1 Receptor stimulation as a treatment strategy for AD and neurodegenerative disorders
11:40 – 11:55  Karl-Heinz Krause (Geneva, Switzerland)
NOX inhibitors as novel therapeutics for the treatment of neurodegenerative diseases
11:55 – 12:05  General discussion

12:05 – 13:30 Lunch

Diabetes, the metabolic syndrome and Alzheimer disease

Oral Communications II
Chairs: Christophe Büla (LS) and Jean-Marie Annoni (GE)
13:50 – 14:05  Ana Martinez (Madrid, Spain)
Enhancing endogenous neurogenesis with GSK3 inhibitors as a new therapeutic strategy for AD
14:05 – 14:20  Annalena Venneri (Hull, UK)
Neuropsychological indicators of response to cholinesterase inhibitor treatment in early AD
14:20 – 14:35  Jakub Hort (Prague, Czech Republic)
Subgroups of mild cognitive impairment have identical spatial memory impairment as found in AD
14:35 – 14:50  Luigia Trabace (Foggia, Italy)
Soluble beta amyloid 1-42: A critical player in producing changes evoking depressive-related state?
14:50 – 15:05  TBA
15:05 – 15:10  Discussion

15:10 – 15:40 Closing remarks

19:00 – 22:30 Speakers dinner (by invitation)

Red: new – need to update
Orange: updated title (matching the abstract)